Revenue from Contracts with Customers (Tables)

3 Months Ended

Dec. 31, 2023

Revenue from Contract with Customer [Abstract]

Schedule of disaggregated revenue by significant business line

	Three months ended December 31,
	2023		2022
Significant Business Line
Multiomics	$	62,720	$	61,089
Core Products (1)		48,886		47,839
Sample & Repository Services		30,119		27,616
B Medical Systems		12,592		41,822
Total revenue	$	154,317	$	178,366

(1) Core Products are Automated Stores, Cryogenic Systems, Automated Sample Tube, and Consumables and Instruments.

Schedule of remaining performance obligations

	As of December 31, 2023
	Less than 1 Year		Greater than 1 Year		Total
Remaining performance obligations	$	50,101	$	20,354	$	70,455